[go: up one dir, main page]

SG11201900461UA - Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage - Google Patents

Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage

Info

Publication number
SG11201900461UA
SG11201900461UA SG11201900461UA SG11201900461UA SG11201900461UA SG 11201900461U A SG11201900461U A SG 11201900461UA SG 11201900461U A SG11201900461U A SG 11201900461UA SG 11201900461U A SG11201900461U A SG 11201900461UA SG 11201900461U A SG11201900461U A SG 11201900461UA
Authority
SG
Singapore
Prior art keywords
international
publication
embryo implantation
date
dosing regimens
Prior art date
Application number
SG11201900461UA
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of SG11201900461UA publication Critical patent/SG11201900461UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0 1110101011111 011101 0 0111111111 100 1111111011111111110 111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/015497 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: A61K 31/40 (2006.01) A61P 5/10 (2006.01) Published: — with international search report (Art. 2 1 (3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/EP2017/068378 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 20 July 2017 (20.07.2017) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/365,147 21 July 2016 (21.07.2016) US 62/527,721 30 June 2017 (30.06.2017) US (71) Applicant: OBSEVA S.A. [CH/CH]; Chemin des Aulx 12, 1228 Plan-les-Ouates (CH). (72) Inventors: LOUMAYE, Ernest; 29 Chemin de la Planta, 1223 Cologny (CH). GOTTELAND, Jean-Pierre; 9 Rue Charles Humbert, 1205 Geneva (CH). Agent: KATZAROV S.A.; Rue des Epinettes 19, 1227 (74) Geneva (CH). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) M IN ON (54) Title: OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVEN- 7 r TING MISCARRIAGE ir) Il (57) : The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrro- 0 ---- lidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The composi- GC tions and methods of the invention can be used to dose subjects with oxytocin antagonists, including (3Z,55)-5-(hydroxymethyl)-1-[(2'- 1-1 © methyl-1,1'-biphenyl- 4-yl)carbonyl]pyrrolidin-3-one 0-methyloxime, among others, so as to improve endometrial receptivity and re- f'1 duce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intracyto- C plasmic sperm injection (ICSI) embryo transfer procedures.
SG11201900461UA 2016-07-21 2017-07-20 Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage SG11201900461UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365147P 2016-07-21 2016-07-21
US201762527721P 2017-06-30 2017-06-30
PCT/EP2017/068378 WO2018015497A2 (en) 2016-07-21 2017-07-20 Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage

Publications (1)

Publication Number Publication Date
SG11201900461UA true SG11201900461UA (en) 2019-02-27

Family

ID=59501409

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900461UA SG11201900461UA (en) 2016-07-21 2017-07-20 Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage

Country Status (15)

Country Link
US (1) US20190247361A1 (en)
EP (2) EP4056178A1 (en)
JP (3) JP7036791B2 (en)
KR (3) KR20190039725A (en)
CN (3) CN115590849A (en)
AU (2) AU2017300026B2 (en)
BR (1) BR112019001047A2 (en)
CA (1) CA3031252A1 (en)
ES (1) ES2898778T3 (en)
IL (1) IL264243B2 (en)
MA (1) MA52548A (en)
MX (1) MX389041B (en)
SG (1) SG11201900461UA (en)
UA (1) UA127283C2 (en)
WO (1) WO2018015497A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118130807A (en) 2018-05-31 2024-06-04 小野药品工业株式会社 Biomarkers for determining the effectiveness of immune checkpoint inhibitors
EP4025207A1 (en) * 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780725A (en) 1971-03-04 1973-12-25 Smith Kline Instr Fetal heartbeat monitoring system with plural transducers in one plane and at different angles thereto
SE432485B (en) 1974-11-11 1984-04-02 Carter Wallace PUT TO DETERMINE PROLACTIN AND AGENTS
IL56342A (en) 1978-12-29 1982-05-31 Zer Tamar Method and means for determining human chorionic gonadotropin in urine
SE430885B (en) 1980-03-24 1983-12-19 Ferring Ab OXYTOCIN DERIVATIVES
US4437467A (en) 1981-12-11 1984-03-20 American Home Products Corporation Apparatus for monitoring fetal heartbeat and the like
DE3363830D1 (en) 1982-12-21 1986-07-03 Ferring Ab Vasotocin derivatives
US4720455A (en) 1985-09-06 1988-01-19 Pitman-Moore, Inc. Progesterone assay method for mammals and monoclonal antibody therefor
WO1991003935A1 (en) 1989-09-22 1991-04-04 Tsi-Mason Research Institute Method and compositions for one-step cryopreservation of embryos
SE9604341D0 (en) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1105469B1 (en) 1998-08-11 2010-09-29 University Of Hawaii Mammalian transgenesis by intracytoplasmic sperm injection
IL160780A0 (en) 2001-09-12 2004-08-31 Applied Research Systems USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
US7815912B2 (en) 2002-06-07 2010-10-19 Ares Trading, S.A. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
EP1646389B1 (en) 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
KR100985449B1 (en) * 2005-05-10 2010-10-05 페링 인터내셔널 센터 에스 에이 Uses of Oxytoxins and / or Vasopressin Antagonists
WO2008051620A2 (en) 2006-10-24 2008-05-02 University Of Hawaii Methods and compositions for intracytoplasmic sperm injection-mediated transgenesis
US7989217B2 (en) 2007-03-29 2011-08-02 Ameritek Usa, Inc. Method for determining hCG levels in fluid samples
WO2010011766A1 (en) 2008-07-23 2010-01-28 Mariposa Biotechnology, Inc. Automated system for cryopreservation of oocytes, embryos, or blastocysts
US9201077B2 (en) * 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
EP2493874A1 (en) 2009-10-30 2012-09-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl]-6- [(1s) - 1 -methylpropyl]-2,5- piperazinedione
CN104254596B (en) 2012-04-16 2016-09-07 康奈尔大学 Automated Intracytoplasmic Sperm Injection Assisted Insemination System
US8937139B2 (en) 2012-10-25 2015-01-20 Chevron Phillips Chemical Company Lp Catalyst compositions and methods of making and using same
HK1213454A1 (en) * 2012-11-26 2016-07-08 Ferring B.V. Method and system for diagnosing uterine contraction levels using image analysis
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) * 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
EP3037101B1 (en) * 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
RU2726414C2 (en) 2015-10-06 2020-07-14 Ферринг Б.В. Novel methods of producing barusiban and intermediate compounds thereof

Also Published As

Publication number Publication date
CN115569132A (en) 2023-01-06
AU2017300026B2 (en) 2023-07-13
EP4056178A1 (en) 2022-09-14
CN109689048A (en) 2019-04-26
IL264243B2 (en) 2023-02-01
JP2024095703A (en) 2024-07-10
JP2019523251A (en) 2019-08-22
EP3487493B1 (en) 2021-09-01
KR20190039725A (en) 2019-04-15
CN115590849A (en) 2023-01-13
MX2019000498A (en) 2019-09-16
JP7036791B2 (en) 2022-03-15
WO2018015497A2 (en) 2018-01-25
AU2023237170A1 (en) 2023-10-19
WO2018015497A3 (en) 2018-03-01
ES2898778T3 (en) 2022-03-08
CA3031252A1 (en) 2018-01-25
AU2017300026A1 (en) 2019-02-28
BR112019001047A2 (en) 2019-04-30
JP2022078194A (en) 2022-05-24
IL264243B (en) 2022-10-01
KR20250079242A (en) 2025-06-04
CN109689048B (en) 2022-10-28
MX389041B (en) 2025-03-20
KR20230165386A (en) 2023-12-05
US20190247361A1 (en) 2019-08-15
EP3487493A2 (en) 2019-05-29
IL264243A (en) 2019-02-28
MA52548A (en) 2021-05-26
UA127283C2 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201907891XA (en) Combination therapy for the treatment or prevention of tumours
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201901633WA (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805001UA (en) Method of treating influenza a
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201900043TA (en) Antibody formulations